158 related articles for article (PubMed ID: 17577103)
1. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.
Derby MA; Zhang L; Chappell JC; Gonzales CR; Callaghan JT; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Mitchell MI
J Cardiovasc Pharmacol; 2007 Jun; 49(6):384-93. PubMed ID: 17577103
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.
Raskin J; Wang F; Pritchett YL; Goldstein DJ
Pain Med; 2006; 7(5):373-85. PubMed ID: 17014595
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
Tianmei S; Knadler MP; Lim MT; Yeo KP; Teng L; Liang S; Pan AX; Lobo ED
Clin Pharmacokinet; 2007; 46(9):767-75. PubMed ID: 17713974
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
Sharma A; Goldberg MJ; Cerimele BJ
J Clin Pharmacol; 2000 Feb; 40(2):161-7. PubMed ID: 10664922
[TBL] [Abstract][Full Text] [Related]
5. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence.
Castro-Diaz D; Palma PC; Bouchard C; Haab F; Hampel C; Carone R; Zepeda Contreras S; Rodriguez Ginorio H; Voss S; Yalcin I; Bump RC;
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Aug; 18(8):919-29. PubMed ID: 17160693
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
[TBL] [Abstract][Full Text] [Related]
7. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
Raskin J; Pritchett YL; Wang F; D'Souza DN; Waninger AL; Iyengar S; Wernicke JF
Pain Med; 2005; 6(5):346-56. PubMed ID: 16266355
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
Chalon SA; Granier LA; Vandenhende FR; Bieck PR; Bymaster FP; Joliat MJ; Hirth C; Potter WZ
Neuropsychopharmacology; 2003 Sep; 28(9):1685-93. PubMed ID: 12784100
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
Thase ME; Tran PV; Wiltse C; Pangallo BA; Mallinckrodt C; Detke MJ
J Clin Psychopharmacol; 2005 Apr; 25(2):132-40. PubMed ID: 15738744
[TBL] [Abstract][Full Text] [Related]
14. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.
Armstrong DG; Chappell AS; Le TK; Kajdasz DK; Backonja M; D'Souza DN; Russell JM
Pain Med; 2007; 8(5):410-8. PubMed ID: 17661854
[TBL] [Abstract][Full Text] [Related]
17. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.
Chappell J; He J; Knadler MP; Mitchell M; Lee D; Lobo E
J Clin Pharmacol; 2009 Dec; 49(12):1456-66. PubMed ID: 19793910
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.
van Kerrebroeck P; Abrams P; Lange R; Slack M; Wyndaele JJ; Yalcin I; Bump RC;
BJOG; 2004 Mar; 111(3):249-57. PubMed ID: 14961887
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
